Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy

A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC).

(2017) K. K. Ang et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer

(2012) Hiroyuki Yasuda et al.   Journal of Thoracic Oncology

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

(2012) Zhao Chen et al.   NATURE

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

(2011) Laura J. Esserman et al.   BREAST CANCER RESEARCH AND TREATMENT

Survival Outcomes After Radiation Therapy for Stage III Non–Small-Cell Lung Cancer After Adoption of Computed Tomography–Based Simulation

(2011) Aileen B. Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324

(2011) George R. Blumenschein et al.   JOURNAL OF CLINICAL ONCOLOGY

The BATTLE Trial: Personalizing Therapy for Lung Cancer

(2011) Edward S. Kim et al.   Cancer Discovery